CVS Health's adherence to ACA mandates impacts Gilead's drug uptake following FDA approval for Yeztugo.

3 reports, 3 independent Updated Aug 22

Gone quiet Reached 3 outlets in its first 24 hours

Reports: 3
Developments: 2
Repetition: 33%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

CVS Health's adherence to ACA mandates impacts Gilead's drug uptake following FDA approval for Yeztugo.

Who's involved

What this event is mainly about

CVS Health FDA Kite

How it developed

Newest first. Tap a step to see who reported it.

Aug 22CVS Health's ACA mandates affect uptake of Gilead's newly FDA-approved drug, Yeztugo.1 source
- Zacks
Aug 21CVS Health declined coverage for Yeztugo drug developed by Gilead Sciences.1 source
- StockStory

Keep exploring

Part of

Gilead Sciences has achieved FDA approval for next-generation CAR T-cell therapies, leveraging the platform influenced by Trump-era tariffs and onshoring trends. All 1 developments

The entities involved

CVS Health
company
- CVS Health confirmed it is retaining both the Caremark pharmacy benefit management unit and the Aetna health insurance business.Thu 00:30
- Aetna reported operational improvements and margin recovery, leading to raised full-year guidance.Wed 23:57
FDA
- Cloudbreak Pharma Inc. intends to meet with the FDA to review its study findings.Thu 04:41
- Legislation requires the FDA to study formula metals, while Donald Trump endorses a candidate focused on economic growth.Thu 02:09
Kite
Oglala Lakota performance artist, visual artist, and composer (born 1990)

Nothing else this week.

Related events

CVS Health, Walgreens, and Rite Aid are facing opioid crisis lawsuits, with a recent ruling stating CVS was not entitled to insurer coverage from AIG and Chubb.Jun 7

Coverage

Newest first; wire copies grouped

Aug 22ZacksGILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo Shares of Gilead Sciences, Inc. (GILD) tumbled 2.2% on Aug. 21, after pharmacy benefit manager CVS Health (CVS) decided not to add the for
Aug 21StockStoryWhy Gilead Sciences (GILD) Shares Are Sliding Today Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS Health will not be adding
Aug 21Investing.comGilead stock falls after CVS holds off adding HIV prevention shot to plans Investing.com -- Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health